p21ras contributes to HIV-1 activation in T-cells  by Baldari, Cosima T. et al.
Volume 304, number 2,3, 261-264 FEB$11164 
© 1992 Federation of Europeaa Biochemical Societies 00145793/9~$5.00 
June 1992 
p21 contributes to HIV-1 activation in T-cells 
Cosima T. BaldarP, Giovanni Macehia b, Annalisa Massone b and John L. Telford b 
"Department of EvolutionaPy Biology, UnivePs#y of Siena, Via Mattioli 4, 53100 Siena, Italy and bLR.I.S., Via Fiorentina 1, 53100 
Siena, haly 
Received 10 April 1992 
Activation of T-cells infected by HIV-I results in activation of long terminal repeat (LTR)-dependent viral transcription and ultimately the 
production of infectious virus, Although full T-cell activation requires a complex series of intracellular signals, including protein kinas¢ C activation. 
calcium mobilisation, and less-well defined lymphokine-induecd signals, the HIV-I LTR can be aetivaled by subsets of these signals. We have studied 
the interaction of these signals in the human lymphoma line, Jurkat, in activation of the HIV-I LTR. The HIV promoter was induced by IL-I 
and phorbol ester activation of PKC but not by a calcium ionol~hore. The ,:onstitutively active form of Ha-ms could replace phorbol ester 
stimulation of the H IV promoter and of a synthetic promoter containing NFtcB binding sites, 
HIV-I; Interleukin; Signal transduction; Cyclospofin A
1, INTRODUCTION 
Human immunodeficiency virus 1 (HIV-1) is a iym- 
photropic retrovirus which is believed to be the causa- 
tive agent of acquired immune deficiency syndrome 
(AIDS) [1,2]. One of the characteristics of HIV-1 infec- 
tion is a very long latency period between infection, as 
evidenced by seroconversion, and onset of clinical dis- 
ease. The virus apparently lies dormant in infected cells 
until some stimulus activates viral expression [3,4]. Per- 
ipheral blood lymphocytes from infected individuals 
produce little or no virus, however, viral expression can 
be activated, and infectious virus recovered, after treat- 
ment with T-cell-activating agents, such as PMA and 
PHA [5,6]. Treatment of HIV-l-infected Jurkat cells 
with T-cell mitogens results in activation of the viral 
promoter contained in the long terminal repeat (LTR), 
and subsequent expression of viral functions [7,8]. The 
viral transactivating protein, tat, then cooperates with 
host proteins to maintain a high level of proviral tran- 
scription [9,10]. Thus a primary event in the transition 
from the asymptomatic phase to outrigh: disease may 
be the activation of host cell transcription factors capa- 
ble of inducing LTR-driven transcription. 
T-Cell activation is a complex process triggered by 
T-cell antigen receptor (TCR) recognition of specific 
antigen in the context of the appropriate histocompati- 
bility. TCR stimulation, plus other ancillary signals 
usually delivered by the antigen presenting cell, results 
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in a series of events involving the release of lymphoki- 
nes, proliferation and maturation to a fully differenti- 
ated immunocompetent cell.A key event in this process 
is the induction of the lymphokine, IL-2, and its cell 
surface receptor, which results in autocrine prolifera- 
tion, and signals a point of commitment after which the 
activating stimuli may be removed without interrupting 
normal differentiation (reviewed in [11,12]). Several in- 
tracellular signalling pathways, including mobilization 
of both monovalent and divalent ions [13,14] and aeti. 
ration of several protein kinases [15-17], are involved 
in T-cell activation, however, activation of protein ki- 
nase C (PKC) [18-20] and mobilization of calcium by 
the TCR [21-24] have been shown to be necessary. 
These two signals in combination with a less-well de- 
fined but independent signal, which can be delivered by 
the lymphokine IL-1 [25], are sufficient o induce full 
IL-2 and IL-2R expression. 
We have studied the induction of HIV LTR-driven 
transcription by T-cell-activating stimuli using an LTR 
reporter gene construct transfected into the human lym- 
phoma line, Jurkat. It has previously been reported that 
IL-1 does not activate the LTR in Jurkat cells [6,26]. We 
now show that this is due to the lack of functional IL-I 
receptors on the surface of these cells. Treatment of 
Jurkat cells co-transfeeted with the LTR reporter con- 
struct, and a construct capable o, ~xw~s,ns ,L-I recep- 
tors, results in activation of the LTR. We have com- 
pared the ability of PKC activation, calcium mobilJsa- 
tion and IL-I stimulation to activate the LTR, and show 
that the LTR responds to subsets of the signals required 
for !L-2 induction. In addition, we have shown that the 
ras protein, which is activated on TCR triggering [27], 
plays a role in LTR activation, and that this effect 
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is likely to be mediated by the NFtcB transcription 
factor. 
2. MATERIALS AND METHODS 
2. I .  ~¢agettts 
Recombinant human IL.lfl from E. ¢'oli [28] was used at 1 n~ml. 
PMA (Sigma) and ionophore, A23187 (Boehringer Mannheim), were 
dissolved in dimethyl sulfoxide at 100/~g/ml and 10 mg/ml, respec- 
tively. PHA (Wellcome Diagnostics, Dartford, UK) was dissolved in 
phosphate-buffered saline at 1 mg/ml, Cyelosporin A (Sandoz. East 
Hanover. N J) was dissolved in ethanol at 10 m~ml. For protein 
determination the kit, BCA, from Pierce was used, Acetyl eoenzyme 
A (Boehringer) and [~Clchloramphenicol (Amersham Internationa!) 
were used for chloramphenicol acetyl transferase (CAT) assays, as 
described by Gorman etal. [29]. ['~H]Acetyl ¢oenzyme A (Du Pont. 
New England Nuclear) and chloramphenicol, dissolved in ethanol at 
50 mlM, were used for CAT assa),s as described [30]. Restriction 
enzymes, Klenow polymerase and T4 DNA ligase (Boeht'inger) were 
used according to the manufacturer's in tructions. 
2,2, PlasmkA" 
An approximately 1.7 kb fragment from the EcoRV site i,a the 
pUC18 polylinker to the Hb~dill site at map position 1.71 of the 
HIV-I LTR was excised from the plasmid, pNL4-3 [31], and sub- 
cloned upstream or the CAT gone in the plasmid, IL2-CAT [32], 
digested with Hindlll and Sinai to remove the IL-2 promoter flag- 
ment, 
pSVT7 is an expression vector containing a polylinker downstream 
of the SV40 earl)' promoter [33], pSVT7/IL.IR has been described 
elsewhere [341. 
The ras expression plasmid was constructed byinsertion of the I0400 
bp C[al/Dral restriction fragment containing the MLV LTR from 
pDOL- [35l into the Hindlll site into the plasmid pT24C3 [36] after 
filling of the overhanging ends with Klenow polymerase. The NFtcB- 
containing plasmid was described as PRDII [37]. 
2.3. Cell c'ufture, transfL, c'tiott~" arid C.,I T assays 
The human lymphoma line. Jurkat, was maintained inRPMI sup- 
plemented with 2 toNI t..glutamine, 20 mM HEPES, pH 7.9, 12.5~,JVI 
2.mercaptoethanol and 10% heat-inactivated (56°C lbr 90 rain) fetal 
calf serum (Seromed, Berlin). The medium used for tranffeclions in- 
eluded 200 U/ml penicillin (Farmitalia, Italy). Transfections were car- 
ried oat using a modification of the DEAE .dcxtran procedure, as 
described [20], scaled dowl~ to one tenth with 1 /.tg of the plasmid 
L'rR/CAT per sample (1×10" Jurkat cells). To avoid error due to 
variation in transfeetion efficiency, comparisons of stimuli or inhib- 
itors were carried out on identical aliquots of single pools of trans- 
fectecl ceils. Cells were allowed to recover for 24 h before activation. 
EGTA or CsA were added when required 30 rain b,.fore stimulation. 
After incubation for 8-16 h cells were collected by centrlfugation, 
washed in TBS, resuspended in 0,25 M TRIS hydrochloride (pH 7.5) 
and extracted by freeze-thawing. Equal amounts of proteins, dc*.er- 
mined according to a modification of the method escribed by Lowry 
[38], were used for CAT assays, CAT enzyme activity was assayed 
using both [*4C]chloramphenlcol, according to Oorman ctal. [29l, and 
['~H]acetyl coenzyme A, according lo Eastman [301, 
3. RESULTS AND DISCUSSION 
Activation or the T-cell antigen receptor with the 
non-specific ligand, PHA, results in a stimulation of  
protein kinase C activity and an increase in intraceiiular 
free calcium concentrations [11,12]. These signals can be 
mimicked by phorbol myristate acetate (PMA), which 
activates OKC [16], and calcium ionophores [39]. Fig. 
1 shows the results of CAT assays of extracts of Jurkat 
cells transfected with a plasmid construct, containing 
the bacterial gone coding for chloramphenicol acetyl 
transferase under the control of the H1V-I LTR (LTR/ 
CAT), after treatment with T-ceil mitogens. Treatment 
with either PMA or PHA resulted in an increase in CAT 
activity (Fig. 1, upper panel, lane:~ 2 and 3) of between 
10-20-fold in several experiments, as deterrained by 
laser densitometry of autoradiograms or 3H incorpora- 
tion into chloramphenicol. A combination of PMA and 
PHA induced LTR/CAT only slightly more than the 
individual stimuli (lane 8). 
Treatment with the calcium ionophore, A23187, re- 
suited in a decrease in the constitutive activity (lane 5) 
and treatment with PMA plus A23187 resulted in less 
CAT activity than PMA alone. We believe that the 
reduction in activity was due to slight toxicity of the 
ionophore after long treatments, ince the quantity of 
protein in the cell extracts was always less than in ex- 
tracts after no treatment or treatment with any or the 
other stimuli. PMA/A23187 treatment of Jurkat cells 
transfected with either an IL-2 promoter/CAT construct 
or an SV40 promoter/CAT construct resulted in sub- 
stantial increases in CAT activity [24], even when the 
protein content of the extracts was slightly reduced. 
We conclude that, unlike the IL-2 promoter, the HIV 
LTR is not activated by increas,,s in intracellular free 
calcium. The LTR, however, responds to either PHA or 
PMA alone, whereas the 1L-2 promoter requires a com- 
bination of these treatments or corrtbinatlons of either 
of these agents with IL-1 [24]. 
The LTR promoter/CAT construct did not respond 
to IL-I either alone or in combination with the other 
mitogens (Fig. 1, upper panel, lanes 4, 6 and 7). This is 
due to a lack of sufficient cell surface 1L-I receptors in 
Jurkat cells [24]. Co-transfection or the LTR construct 
with a construct capable of expressing type-I IL-1 recep. 
tors resulted in a response to IL-I. The lower panel of 
Fig. 1 shows the results of CAT assays of Jurkat cells 
co-transfected with the LTR/CAT construct and the 
IL-IR construct reated with different stimuli. In the 
experiment shown IL-I alone resulted in an approxi- 
mately 10-fold increase in CAT activity compared with 
13-fold by PHA and l l-fold by PMA (Fig. 1, lower 
panel, lanes 2, 3 and 4). IL-1 in combination with PHA 
or PMA resulted in induction approximately equal to 
the sum of the individual treatments (Fig. 1, lower 
panel, lanes 6 and 7). Note that the absolute level and 
relative induction of CAT activity varied between ex- 
periments, at least in part due to variations in transfee- 
tion efficiency. Comparisons in any single experiment 
were however made on aliquots of a single pool of 
transfected cells. 
Tiaus the HiV-i LTR responds, like the IL-2 pro- 
motel', to PMA, PHA and IL-I but does not respond 
to increases in calcium induced by the calcium iono- 
phore. Activation or [L-2 expression by PHA is, how- 
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Fig, 1, Acrid, orion of the HIV LTR in Jurkat cells. CAT assays of 
Jurkat cells co-transfected with the plasmid LTR/CAT and either the 
control plasmid, pSVI'7 (upper panel), or the same plasmid containing 
the eDNA for the haman IL-I receptor (lower panel). The samples 
were activated as shown below each lane. PH=PHA (2 /zglml); 
PM=PMA (10 ng/nd); IL=IL-I~ (l ng/ml); A=A23187 (1 pg/ml), 
ever, dependent on calcium [24]. To investigate whether 
activation ofthe LTR by PHA involves calcium we have 
treated Jurkat cells, after co-transfection with the LTR/ 
CAT construct and the IL-I R construct, with the vari- 
ous stimuli in the presence of EGTA. As can be seen 
from the results hown in Fig. 2 only the PHA induction 
is substantially abrogated in the presence of EGTA. 
CAT activity in extracts of cells treated with EGTA 
showed a slight general reduction, which we believe is 
due to toxicity of long incubations in EGTA, however, 
the relative inductions, compared to the LTR constitu- 
tive activity, varied little for treatments with PMA or 
IL-I. As with the IL-2 promoter calcium was required 
for PHA activation of the LTR. A similar specific re- 
duction of  the PHA-induced signal was observed when 
the cells were activated in the presence of the immuno- 
suppressive drug, Cyclosporin A (Fig. 2), which blocks 
calcium-dependent pa hways of gene induction in these 
cells [24]. 
It has recently been reported that TCR triggering by 
PHA results in an increase in the active GTP bound 
form of p21 ~-~'~:'~ [27], and that a constitutively active 
form of p21H~'v~ contibutes to IL-2 gene activation in 
a murine T-cell line [40]. To investigate a possible role 
for ras proteins in HIV LTR activation we have co- 
transfeeted Jurkat cells with the LTR/CAT construct 
and a construct which codes for the T24 oncogenic form 
of p21H`''r"'. The results of CAT assays of cell extracts 
after various treatments are shown in Fig. 3. In the 
presence of T24 constitutive CAT activity was clearly 
increased. Comparison of the CAT activity in the pres- 
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Fig. 2. LTR activation i the presence of EGTA and cyclosporin. CAT 
assays of Jurkat cells transfected with the plasmid, LTR/CAT. and 
activated in the presence of 500 ng/ml cyclosporin A or 3 mM EGTA, 
PHA. 2pg/ml; PMA, 10 ng/ml; IL-lfl. 1 nglml. Samples were assayed 
for CAT activity using [3H]acetyl-CoA, and counted in the linear ange 
of the reaction, The numbers on each column express the -fold stimu- 
lation of activated samples to the control, non.activated sample for 
each group. 
ence or absence of T24 by laser densitometry of the 
autoradiographs from several experiments revealed that 
T24 resulted in a 2-3-fold induction of the LTR. The 
presence of T24 had little effect on CAT activity in 
extracts of cells treated with PMA. In the experiment 
shown the PMA-induced CAT activity was slightly re- 
duced in cells expressing T24. Expression of T24, how- 
ever, resulted in an increase in IL-l-induced LTK/CAT 
activity in cells co-transfected with the IL-I R gene (be- 
tween 30-60% in different experiments). Thus T24 does 
not increase PMA activation but augments both consti- 
tutive and IL-l-induced CAT activity. 
On the basis of its synergism with IL-I and A23187, 
Baldari et al. [40] have suggested that activated p21 r=' 
can replace the signal delivered by PMA in activation 
of the IL-2 protnoter in EL4 cells. Our results are con- 
sistent with this hypothesis since T24 did not augment 
the CAT activity achieved with saturating doses of 
PMA but did augment the IL-I signal. 
The HIV enhancer contains two copies of a sequence 
capable of  binding the NFxB transcription factor, and 
these sequences are involved in LTR inducability [26]. 
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Fig. 3, Onco~enie p21 ~' contributes to HIV LTR activation. CAT 
assays of Jurkat cells co.lransfected with the plasmid. LTR/CAT. and 
either the control plasmid, pDOL- tlefi), or the eorrcspondinl~ eoJ~- 
struct encoding the T24 oncogenic form of Ha.ras (right). Tile samples 
were activated as shown above ach lane. PM=PMA 10 ng/ml; IL=I L- 
Ift I n~ml.  
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Fig. 4. NFtcB is activated by oneogeni¢ p21 ~. CAT assays of Jurkat 
cells co-transfected with the plasmid, NFtcB/CAT, and either the con- 
trol plasmid, pDOL- (left), or the ~rresponding construct encoding 
the T24 oncogenic form or Ha-ras (right). The samples were activated 
as shown above each lane. PM=PMA 10 n~ml; IL=IL-Ifl 1 n~/ml. 
We have asked whether NF~rB may be involved in ras- 
mediated HIV induction in Jurkat cells as it appears to 
be in 1L-2 induction in EL4 cells. We have co-tram. 
leered Jurkat cells with the T24 construct and a con- 
struct containing the CAT gene under the control of  a 
synthetic promoter containing several copies of the 
NFtcB binding site. In the absence of induction or T24 
no CAT activity was detected (Fig. 4). Co-transfection 
with T24 resulted in detectable CAT activity in the ab- 
sence of stimuli. As with the LTR CAT, T24 had no 
significant effect on PMA induction, but IL-1 induction 
was increased by between 40--90% in several experi- 
ments. Thus the NFtcB promoter esponded to T24 and 
stimulation with PMA and IL-I in a manner similar to 
that of the HIV LTR. 
In conclusion the HIV LTR can be activated by sig- 
nals which, alone, are not normally sufficient for full 
T-cell activation. Although induction, mediated by the 
TCR, is dependent on calcium; artificially increasing 
intracellular free calcium using a calcium ionophore 
does not increase constitutive or PMA-induced expres- 
sion. As with the IL-2 promoter, T24 ras can at least in 
part replace the PMA signal, and the transcription fac- 
tor NFtcB is likely to be involved. Clearly the HIV LTR 
has evolved to tak~ advamage of important T-cell tran- 
scription mechanisms in a fashion which is less regu- 
lated than the IL-2 promoter, 
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